Nivalis IPO nets $88M

Boulder biotech Nivalis Therapeutics Inc. said last week's IPO raised more than $88 million. Nivalis shares (NASDAQ: NVLS) began trading last Wednesday. The company, which is concentrating on treating people with cystic fibrosis, said it sold 6,325,000 shares of its common stock at $14 per share. The total amount is before underwriting commission and discounts and offering expenses. In addition to cystic fibrois, the company said it will work on pharmaceuticals to "develop therapeutics for patients…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news